
Advanced Enzyme Analyst Review 2027: Revenue Up 16%, Buyback Done and the Stock at 17 Times Earnings
Updated: 18 Nov 2026 • 9:42 am
Posted by:

Advanced Enzyme Technologies Stock Snapshot (17 Nov 2026 close)
- Current Market Price (CMP): ₹283.15
- 52-Week High / Low: ₹419.00 / ₹246.80
- Market Capitalisation: ₹3,101 crore
- P/E Ratio vs Industry P/E: 17.4 vs 40.1
- Latest Quarter (Q2 FY27) Revenue: ₹214.51 crore
- Latest Quarter (Q2 FY27) Net Profit: ₹51.17 crore
Quick Answer: The Advanced Enzyme analyst review 2027 shows steady growth at a modest valuation. Q2 FY27 revenue rose about 16% to ₹214.51 crore and profit rose about 14% to ₹51.17 crore, while the company completed a ₹69.7 crore share buyback in October 2026. No recent report from a named brokerage could be verified, so there is no reliable published Advanced Enzyme share price target 2027. At ₹283.15, the stock trades about 32% below its 52-week high and near 17 times earnings, against an industry P/E of about 40.
The Advanced Enzyme analyst review 2027 covers India's largest enzyme maker, which supplies enzymes and probiotics for human nutrition, animal feed and industrial processing. People searching for an Advanced Enzyme share price target 2027 will find limited named coverage, so this review relies on results, the buyback and segment trends.
Advanced Enzyme Technologies closed at ₹283.15 on 17 November 2026, about 32% below its 52-week high of ₹419 and about 15% above its low of ₹246.80. This Advanced Enzyme analyst review 2027 covers the September quarter, the business, capital returns and the Advanced Enzyme stock outlook 2027.
Click Here – Get Free Investment Predictions
What Analysts Say in the Advanced Enzyme Analyst Review 2027
| Brokerage | Rating | Target Price | Date |
|---|---|---|---|
| No verified recent coverage | Not available | Not available | As of November 2026 |
No FY27 brokerage report with a named author, rating and target could be traced. Foreign investors own about 27% of the company, so it is followed by institutions, but published research with dated targets is not available in the public domain.
That shapes the Advanced Enzyme analyst review 2027. The most useful signal from the company itself is the buyback, which set a maximum price of ₹500 per share. That was about 54% above the price before the announcement and about 77% above the current price. A buyback cap is not a target, but it shows where the board was willing to buy.
Q2 FY27 Results in the Advanced Enzyme Analyst Review 2027
| Quarter | Total Income | EBITDA | Net Profit |
|---|---|---|---|
| Sep 2026 (Q2 FY27) | ₹223.23 crore | ₹80.84 crore | ₹51.17 crore |
| Jun 2026 (Q1 FY27) | ₹202.81 crore | ₹63.99 crore | ₹38.59 crore |
| Mar 2026 (Q4 FY26) | ₹210.60 crore | ₹70.45 crore | ₹45.25 crore |
| Dec 2025 (Q3 FY26) | ₹180.42 crore | ₹57.82 crore | ₹43.18 crore |
| Sep 2025 (Q2 FY26) | ₹194.81 crore | ₹70.34 crore | ₹44.73 crore |
Revenue from operations rose about 16% to ₹214.51 crore from ₹184.53 crore. EBITDA on the data above rose about 15% to ₹80.84 crore, a margin near 36% of total income. Net profit rose about 14% to ₹51.17 crore, the highest in the last five quarters.
The rebound from Q1 was sharp. Q1 FY27 revenue grew only about 2% and profit was about ₹37 crore to ₹39 crore. For the Advanced Enzyme analyst review 2027, Q2 shows growth returning after a slow start to the year.
How Advanced Enzyme Makes Money
- Human nutrition: digestive enzymes, probiotics and nutraceutical ingredients, the largest segment at about ₹128.5 crore in Q2 FY27, up about 6%.
- Animal nutrition: feed enzymes that improve digestion in poultry and livestock, about ₹26.5 crore in Q2, up about 37%.
- Industrial processing: enzymes for food processing, textiles, baking and other industrial uses.
- Global footprint: a large share of revenue comes from the US and other overseas markets.
FY26 revenue rose to about ₹781 crore from ₹670 crore in FY25, and profit rose to about ₹174 crore from ₹134 crore. Operating cash flow was about ₹157 crore in FY26, close to profit. High margins and steady cash are the strongest features in the Advanced Enzyme analyst review 2027.
Growth Triggers in the Advanced Enzyme Analyst Review 2027
- Buyback completed: the company bought back 24,10,906 shares at an average of about ₹289 between 14 August and 30 October 2026, using 99.99% of the ₹69.7 crore limit.
- Animal nutrition growth: revenue up about 37% in Q2 FY27.
- Subsidiary consolidation: the board approved buying the remaining stake in JC Biotech to make it a wholly owned unit.
- Dividend: a yield of about 1.9%, with debt to equity near 0.03.
- Foreign support: foreign investors raised their stake to 26.65% from 25.41%, a steady base in the Advanced Enzyme analyst review 2027.
Key Risks in the Advanced Enzyme Analyst Review 2027
- Slow core growth: human nutrition, the largest segment, grew only about 6%.
- Uneven quarters: Q1 FY27 revenue grew only about 2%.
- Export exposure: currency moves and US demand affect a large share of sales.
- Domestic exit: domestic institutions cut their stake to 1.89% from 6.41%.
- Modest return on equity: about 10.3%, held down by a large cash and equity base.
- No research coverage: no named targets to anchor expectations.
Compare Advanced Enzyme With Biotech and Pharma Stocks on the Univest Screener
Advanced Enzyme Analyst Review 2027: Stock at a Glance
| Metric | Value |
|---|---|
| Share Price (17 Nov 2026 close) | ₹283.15 |
| 52-Week High / Low | ₹419.00 / ₹246.80 |
| Market Capitalisation | ₹3,101 crore |
| P/E (TTM) vs Industry | 17.4 vs 40.1 |
| Price to Book | 1.86 |
| Book Value per Share | ₹151.93 |
| Return on Equity | 10.26% |
| Debt to Equity | 0.03 |
| Dividend Yield | 1.93% |
| FY26 Revenue / Net Profit | ₹780.6 crore / ₹173.6 crore |
A P/E near 17 is well under half the industry level of about 40, and price to book value is about 1.9. For a company with high margins and almost no debt, the Advanced Enzyme analyst review 2027 points to a valuation that reflects slow growth more than weak quality.
Shareholding Trend
| Holder | Sep 2025 | Sep 2026 | Change |
|---|---|---|---|
| Promoters | 43.07% | 43.56% | +0.49 pts |
| Foreign Investors (FII) | 25.41% | 26.65% | +1.24 pts |
| Domestic Institutions (DII) | 6.41% | 1.89% | -4.52 pts |
| Public | 25.10% | 27.90% | +2.80 pts |
The Rathi family promoter group holds 43.56%, with Vasant Rathi at 26.87% and a family generation trust at 6.75% after an internal reshuffle. Promoter share rose slightly as the buyback reduced the share count. Domestic funds sold most of their stake, while foreign holders added, which split institutional views in the Advanced Enzyme analyst review 2027 period.
What to Watch After the Advanced Enzyme Analyst Review 2027
- Human nutrition growth: whether the largest segment speeds up from about 6%.
- Animal feed: whether the 37% growth in animal nutrition holds.
- Margins: EBITDA margin trends after the strong Q2.
- Capital use: further buybacks, dividends or acquisitions after the ₹69.7 crore programme.
- Research coverage: a named note would give an Advanced Enzyme share price target 2027 reference.
Final Word on the Advanced Enzyme Analyst Review 2027
The Advanced Enzyme analyst review 2027 shows a debt-free, high-margin enzyme maker with revenue up about 16% and profit up about 14% in Q2 FY27. It returned cash through a completed buyback and trades at about 17 times earnings, far below its industry.
The Advanced Enzyme stock outlook 2027 depends on faster growth in human nutrition and steady margins. With no verified brokerage target, quarterly results will drive the stock. Univest does not give a buy or sell call.
Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions
What does the Advanced Enzyme analyst review 2027 show?
It shows steady growth, a completed buyback and a low valuation. Q2 FY27 revenue rose about 16% to ₹214.51 crore and profit rose about 14% to ₹51.17 crore. The P/E is about 17.4 against an industry figure of about 40.
Is there an Advanced Enzyme share price target 2027 from brokerages?
No recent report with a named rating and target could be verified as of November 2026. The company's buyback set a maximum price of ₹500, which is not a target. The stock closed at ₹283.15 on 17 November 2026.
What were the details of the Advanced Enzyme buyback?
The open market buyback ran from 14 August to 30 October 2026 with a limit of ₹69.7 crore. The company bought 24,10,906 shares at an average price of about ₹289. It used 99.99% of the approved amount.
What does Advanced Enzyme sell?
It sells enzymes and probiotics for human nutrition, animal feed and industrial processing. Human nutrition earned about ₹128.5 crore in Q2 FY27 and animal nutrition about ₹26.5 crore. FY26 revenue was about ₹781 crore.
Is Advanced Enzyme undervalued, based on the Advanced Enzyme analyst review 2027?
The P/E of about 17.4 and price to book of about 1.9 are low against the industry. Return on equity is about 10.3%, and growth has been uneven. Univest does not give a view on whether the stock is undervalued.
What risks does the Advanced Enzyme analyst review 2027 highlight?
The main risks are slow growth in human nutrition, uneven quarters and export exposure. Q1 FY27 revenue grew only about 2%. Domestic institutions cut their stake to 1.89% from 6.41%.
What should investors track after the Advanced Enzyme analyst review 2027?
Track human nutrition growth, which was about 6% in Q2 FY27, and whether animal nutrition keeps growing near 37%. Watch margins and capital returns after the buyback. A first named brokerage note would add a reference point.
Recent Articles

Andhra Paper Analyst Review 2027: Back to Profit in Q2, Stock at 0.64 Times Book and a Pollution Penalty Under Appeal
18 November 2026

Amrutanjan Analyst Review 2027: Q2 Profit Up 24%, Hygiene Grows Fast and the Stock Sits Near Its Low
18 November 2026

Amines and Plasticizers Analyst Review 2027: Profit Up 35% in Q2, Thin Margins and Zero Institutional Holding
18 November 2026

Alok Industries Analyst Review 2027: Revenue Up 15%, Loss Widens to ₹208 Crore and Net Worth Stays Negative
18 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Andhra Paper Analyst Review 2027: Back to Profit in Q2, Stock at 0.64 Times Book and a Pollution Penalty Under Appeal
Amrutanjan Analyst Review 2027: Q2 Profit Up 24%, Hygiene Grows Fast and the Stock Sits Near Its Low
Amines and Plasticizers Analyst Review 2027: Profit Up 35% in Q2, Thin Margins and Zero Institutional Holding
Alok Industries Analyst Review 2027: Revenue Up 15%, Loss Widens to ₹208 Crore and Net Worth Stays Negative
Allied Digital Analyst Review 2027: Revenue Up 14%, Profit Down 18% and the Stock Below Book Value
Popular this week
Allcargo Logistics Analyst Review 2027: A Smaller, Domestic Company After the Split, With Profit Back at ₹18 Crore

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





